Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer

NCT00010322 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.

NCT NCT00010322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00010322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Atamestane Plus Toremifene in Metastatic Breast Cancer
Lead sponsor
Intarcia Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2000
Completion date
May 31, 2001
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer